Compare iShares International Treasury Bond ETF (IGOV) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs GeneDx Holdings Corp — how do they compare? iShares International Treasury Bond ETF trades at $39.67 (market cap $1.30B), while GeneDx Holdings Corp trades at $67.75 (market cap $2.02B). The key difference: GeneDx Holdings Corp is the larger of the two by market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares International Treasury Bond ETF for 92 Days and GeneDx Holdings Corp for 19 Days on average.
| IGOV | WGS | |
|---|---|---|
Market Cap | $1.30B | $2.02B |
Volume | 693,740 | 734,640 |
Sector | Fixed Income | Health |
52-Week High | $42.99 | $167.51 |
52-Week Low | $39.65 | $34.51 |
Typical Hold Time | 92 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV trades at $39.75 with minimal daily movement (+0.13%). Technical indicators show a bearish bias with moving averages signaling caution, though oscillators remain neutral. The stock faces significant resistance at $40 across multiple levels. Financial ratios are unavailable in current data, limiting fundamental assessment.
The stock's outlook remains cautious due to technical weakness and limited fundamental visibility. Rising bond yields create macroeconomic headwinds for equities, though inverse Treasury ETFs may benefit. Investors require updated financial disclosures to properly evaluate valuation and growth prospects amid current market volatility.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
